Profiling preexisting antibodies in patients treated with anti–PD-1 therapy for advanced non–small cell lung cancer
Y Toi, S Sugawara, J Sugisaka, H Ono… - JAMA …, 2019 - jamanetwork.com
Importance Administration of anti–programmed cell death protein 1 (anti–PD-1) is now
standard therapy in advanced non–small cell lung cancer (NSCLC). However, immune
checkpoint inhibitors, including anti–PD-1, have not been assessed in patients with
subclinical disease with advanced NSCLC, and no useful clinical biomarkers have been
associated with immune-related adverse events (irAEs) among these patients treated with
anti–PD-1. Objective To assess the safety and efficacy of anti–PD-1 treatment in patients …
standard therapy in advanced non–small cell lung cancer (NSCLC). However, immune
checkpoint inhibitors, including anti–PD-1, have not been assessed in patients with
subclinical disease with advanced NSCLC, and no useful clinical biomarkers have been
associated with immune-related adverse events (irAEs) among these patients treated with
anti–PD-1. Objective To assess the safety and efficacy of anti–PD-1 treatment in patients …